Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Joerg Willuda"'
Autor:
Jessica Pinkert, Hans-Henning Boehm, Mark Trautwein, Wolf-Dietrich Doecke, Florian Wessel, Yingzi Ge, Eva Maria Gutierrez, Rafael Carretero, Christoph Freiberg, Uwe Gritzan, Merlin Luetke-Eversloh, Sven Golfier, Oliver Von Ahsen, Valentina Volpin, Antonio Sorrentino, Anchana Rathinasamy, Maria Xydia, Robert Lohmayer, Julian Sax, Ayse Nur-Menevse, Abir Hussein, Slava Stamova, Georg Beckmann, Julian Marius Glueck, Dorian Schoenfeld, Joerg Weiske, Dieter Zopf, Rienk Offringa, Bertolt Kreft, Philipp Beckhove, Joerg Willuda
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), a cell surface receptor, is expressed on normal epithelial tissue and highly expressed in cancers of high unmet medical need, such as non-small cell lung, pancreatic, and colorectal
Externí odkaz:
https://doaj.org/article/b51b522082204e19b3b78844000d71d5
Autor:
David Kiewlich, Jianhuan Zhang, Cynthia Gross, Wei Xia, Brent Larsen, Ronald R. Cobb, Sandra Biroc, Jian-Ming Gu, Takashi Sato, David R. Light, Tara Heitner, Joerg Willuda, David Vogel, Felipe Monteclaro, Andrzej Citkowicz, Steve R. Roffler, Deborah A. Zajchowski
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 8, Iss 1, Pp 18-30 (2006)
The EphA2 receptor tyrosine kinase has been shown to be over-expressed in cancer and a monoclonal antibody (mAb) that activates and down-modulates EphA2 was reported to inhibit the growth of human breast and lung tumor xenografts in nude mice. Reduct
Externí odkaz:
https://doaj.org/article/8033c22a57da4a11ab4c7b29ceb0609c
Autor:
Hans-Georg Lerchen, Beatrix Stelte-Ludwig, Charlotte Kopitz, Melanie Heroult, Dmitry Zubov, Joerg Willuda, Thomas Schlange, Antje Kahnert, Harvey Wong, Raquel Izumi, Ahmed Hamdy
Publikováno v:
Cancers; Volume 14; Issue 2; Pages: 391
Cancers
Cancers, Vol 14, Iss 391, p 391 (2022)
Cancers
Cancers, Vol 14, Iss 391, p 391 (2022)
Simple Summary Many cancer drugs are cytotoxic, which means that they kill cancer cells effectively but are also toxic to normal cells. To overcome this problem, we designed a novel compound, VIP236, which consists of three components. The first part
Autor:
Jessica Pinkert, Hans-Henning Boehm, Mark Trautwein, Wolf-Dietrich Doecke, Florian Wessel, Yingzi Ge, Eva Maria Gutierrez, Rafael Carretero, Christoph Freiberg, Uwe Gritzan, Merlin Luetke-Eversloh, Sven Golfier, Oliver Von Ahsen, Valentina Volpin, Antonio Sorrentino, Anchana Rathinasamy, Maria Xydia, Robert Lohmayer, Julian Sax, Ayse Nur-Menevse, Abir Hussein, Slava Stamova, Georg Beckmann, Julian Marius Glueck, Dorian Schoenfeld, Joerg Weiske, Dieter Zopf, Rienk Offringa, Bertolt Kreft, Philipp Beckhove, Joerg Willuda
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 11, Iss 1 (2022)
article-version (VoR) Version of Record
OncoImmunology, Vol 11, Iss 1 (2022)
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), a cell surface receptor, is expressed on normal epithelial tissue and highly expressed in cancers of high unmet medical need, such as non-small cell lung, pancreatic, and colorectal
Autor:
Dmitry Zubov, Raquel Izumi, Hans-Georg Lerchen, Joerg Willuda, Thomas Schlange, Mélanie Héroult, Charlotte Kopitz, Beatrix Stelte-Ludwig, Antje Kahnert, Ahmed Hamdy
Publikováno v:
Cancer Research. 81:1314-1314
To improve tumor selectivity of cytotoxic agents we designed small molecule drug conjugates leveraging two independent mechanisms of targeted delivery by utilizing an integrin binder for tumor homing and release of the active drug by proteases presen
Autor:
Joerg Willuda, Hans-Henning Boehm, Jessica Pinkert, Mark Trautwein, Wolf-Dietrich Doecke, Oliver von Ahsen, Karl Ziegelbauer, Rienk Offringa, Bertolt Kreft, Philipp Beckhove
Publikováno v:
Cancer Research. 79:LB-075
CEACAM6 (CD66c) is a novel immune checkpoint regulator suppressing the activity of effector T cells against tumors. CEACAM6 is expressed on tumor cells of multiple malignancies e.g.adenocarcinomas of the lung, colon, pancreas and stomach. In these tu
Autor:
Dietger Stibenz, Thore Dietrich, Christiane Schneemann, Thomas Hucko, Joerg Willuda, Eckart Fleck, Kristof Graf, Hans D. Menssen, Marleen Neumann, Andreas Menrad, Kirstin Atrott
Publikováno v:
Atherosclerosis. 220:329-336
Recent studies indicate that regulatory T cells (Tregs) attenuate murine atherosclerosis. Since interleukin (IL)-2 induces Tregs proliferation, we tested the impact of L19-IL2, a fusion antibody specific to extra-domain B of fibronectin (ED-B) contai
Autor:
Julian Glueck, Christoph Freiberg, Dieter Zopf, Hans-Henning Boehm, Heiner Apeler, Wolf-Dietrich Doecke, Florian Wessel, Joerg Weiske, Beckhove Philipp, Mark Trautwein, Ruprecht Zierz, Joerg Willuda, Sabine Wittemer-Rump, Pinkert Jessica, Ziegelbauer Karl, Uwe Gritzan, Yingzi Ge, Oliver von Ahsen, Bertolt Kreft, Gutierrez Eva-Maria, Sven Golfier, Rienk Offringa
Publikováno v:
Cancer Research. 78:1771-1771
CEACAM6 (CD66c) was previously shown to act as a novel immune checkpoint regulator suppressing the activity of effector T cells against tumors (Witzens-Harig et al., Blood 2013). CEACAM6 is a GPI-linked protein that is strongly expressed at the tumor
Autor:
Christoph Niederalt, Mark Trautwein, Joerg Willuda, Christian Scheerans, Sabine Wittemer-Rump, Merlin Verena Luetke-Eversloh, Wolf-Dietrich Doecke, Clemens Guenther
Publikováno v:
Cancer Research. 78:2791-2791
BAY 1834942 is an immunostimulatory function-blocking (fb) antibody (Ab) against the target carcinoembryonic antigen related cell adhesion molecule 6 (CEACAM6) expressed on tumor cells in multiple cancer indications. The suggested mode of action of B
Autor:
Joerg Willuda, Wei Xia, Felipe Monteclaro, Takashi Sato, Sandra Biroc, Cynthia Gross, David R. Light, David Vogel, Jian-ming Gu, Brent R. Larsen, Ronald R. Cobb, Jianhuan Zhang, Andrzej Citkowicz, Deborah A. Zajchowski, David Kiewlich, Steve R. Roffler, Tara Heitner
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 8, Iss 1, Pp 18-30 (2006)
The EphA2 receptor tyrosine kinase has been shown to be over-expressed in cancer and a monoclonal antibody (mAb) that activates and down-modulates EphA2 was reported to inhibit the growth of human breast and lung tumor xenografts in nude mice. Reduct